Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Hamid on the Progression of Therapy for Metastatic Prostate Cancer

March 17th 2020

Anis Hamid, MBBS, discusses the progression of therapy for metastatic prostate cancer.

Analysis Yields Potential New Precision Medicine Path in mHSPC

March 17th 2020

Anis Hamid, MBBS, discusses the analysis of genomic profiling from the phase III CHAARTED trial, and the burgeoning potential of precision medicine in metastatic hormone sensitive prostate cancer.

Dr. Gomella on the State of Genetic Testing and Screening in Prostate Cancer

March 14th 2020

Leonard G. Gomella, MD, professor, chair, Department of Urology, and director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the state of genetic testing in prostate cancer.

Gomella Offers Guidance on Screening, Genetic Testing in Prostate Cancer

March 14th 2020

Leonard G. Gomella, MD, discusses the state of genetic testing in prostate cancer, shares his recommendations for screening, and provides perspective on where the field is headed.

Novel Imaging Method Proves Effective in Detecting Prostate Cancer Recurrence

March 13th 2020

In a recent study, investigators at UCLA and UCSF have demonstrated high positive predictive value for a new imaging technique for localizing recurrent prostate cancer.

Dr. Antonarakis on Updated Analysis of the KEYNOTE-199 Trial in mCRPC

March 13th 2020

Emmanuel S. Antonarakis, MBBCh, discusses updated data from the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Dr. McKay on the Real-World Utilization of Radium-223 in mCRPC

March 13th 2020

Rana R. McKay, MD, discusses results from an analysis examining the real-world utilization of radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Dr. Oh on Design and Results of the PRINT Trial in Castration-Resistant Prostate Cancer

March 12th 2020

William K. Oh, MD, discusses the design and findings of the PRINT trial in metastatic castration-resistant prostate cancer.

Grivas Shares Insight on Biomarker Research, Combo Strategies in Prostate Cancer

March 11th 2020

Petros Grivas MD, PhD, discusses biomarker-driven and combination research in metastatic castration-resistant prostate cancer.

Dr. Freedland on the Importance of Conducting Real-World Analyses in Prostate Cancer

March 10th 2020

Stephen J. Freedland, MD, discusses the importance of conducting real-world analyses in prostate cancer.

Dr. Grivas on Cabazitaxel/Enzalutamide in mCRPC

March 7th 2020

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Freedland on Standardized PSA Testing in Prostate Cancer

March 6th 2020

Stephen J. Freedland, MD, discusses the importance of standardizing prostate-specific antigen testing in prostate cancer.

Dr. Armstrong on the Utility of Liquid Biopsies in mCRPC

March 5th 2020

Andrew J. Armstrong, MD, discusses the utility of liquid biopsies in metastatic castration-resistant prostate cancer.

Real-World Analysis Confirms Enzalutamide Efficacy in mCRPC

March 4th 2020

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in patients with metastatic castration-resistant prostate cancer.

Antidepressant Shows Antitumor Potential in Prostate Cancer

March 4th 2020

The antidepressant phenelzine showed antitumor activity in patients with biochemical recurrent castrate-sensitive prostate cancer.

Dr. Dahut on an NCI-Led Study Using MRI Screening to Detect Prostate Cancer

March 4th 2020

William L. Dahut, MD, senior investigator and section chief, Genitourinary Malignancies Branch, head, Prostate Cancer Clinical Research Section, clinical director and scientific director for clinical research, Center for Cancer Research, National Cancer Institute (NCI), discusses an NCI-led study that is using screening to detect prostate cancer.

PROs Further Support Hypofractionated RT in Nonmetastatic Prostate Cancer

March 3rd 2020

The use of moderately hypofractionated radiation therapy demonstrated no statistically significant differences in functional outcomes compared with conventionally fractionated radiation therapy, further cementing hypofractionated radiation therapy as a standard approach for patients with nonmetastatic prostate cancer.

Dr. Powles on the Mission of the Uromigos Twitter Group

February 29th 2020

Thomas Powles, MD, MBBS, MRCP, discusses the mission and goals for the Uromigos Twitter group.

Dr. McKay on a Real-World Analysis of Radium-223 in mCRPC

February 27th 2020

Rana R. McKay, MD, discusses the results of a real-world analysis of radium-223 in patients with metastatic castration-resistant prostate cancer.

Dr. Agarwal on Developing Biomarkers of Response to Cabozantinib/Atezolizumab in mCRPC

February 27th 2020

Neeraj Agarwal, MD, discusses the importance of developing biomarkers of response to the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.